Prognoses and clinical outcomes of primary and recurrent uveal melanoma

Jee Hung Kim, Su Jin Shin, Soo Jin Heo, Eun Ah Choe, Chang Gon Kim, Minkyu Jung, Ki Chang Keum, Jinsook Yoon, Sungchul Lee, Sang Joon Shin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood of recurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters. Materials and Methods Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression- free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy. Results Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)-negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival. Conclusion Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.

Original languageEnglish
Pages (from-to)1238-1251
Number of pages14
JournalCancer Research and Treatment
Volume50
Issue number4
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

Recurrence
Survival
BRCA1 Protein
Neoplasms
Uveal melanoma
Metastasectomy
Sex Ratio
Therapeutics
Disease-Free Survival
Radiotherapy
Multivariate Analysis
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, J. H., Shin, S. J., Heo, S. J., Choe, E. A., Kim, C. G., Jung, M., ... Shin, S. J. (2018). Prognoses and clinical outcomes of primary and recurrent uveal melanoma. Cancer Research and Treatment, 50(4), 1238-1251. https://doi.org/10.4143/crt.2017.534
Kim, Jee Hung ; Shin, Su Jin ; Heo, Soo Jin ; Choe, Eun Ah ; Kim, Chang Gon ; Jung, Minkyu ; Keum, Ki Chang ; Yoon, Jinsook ; Lee, Sungchul ; Shin, Sang Joon. / Prognoses and clinical outcomes of primary and recurrent uveal melanoma. In: Cancer Research and Treatment. 2018 ; Vol. 50, No. 4. pp. 1238-1251.
@article{878f4da670c64f3e867a49d4253648c9,
title = "Prognoses and clinical outcomes of primary and recurrent uveal melanoma",
abstract = "Purpose Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood of recurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters. Materials and Methods Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression- free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy. Results Forty-nine patients (21.7{\%}) had distant recurrences, which occurred most frequently in the liver (87.7{\%}). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)-negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival. Conclusion Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.",
author = "Kim, {Jee Hung} and Shin, {Su Jin} and Heo, {Soo Jin} and Choe, {Eun Ah} and Kim, {Chang Gon} and Minkyu Jung and Keum, {Ki Chang} and Jinsook Yoon and Sungchul Lee and Shin, {Sang Joon}",
year = "2018",
month = "10",
day = "1",
doi = "10.4143/crt.2017.534",
language = "English",
volume = "50",
pages = "1238--1251",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

Kim, JH, Shin, SJ, Heo, SJ, Choe, EA, Kim, CG, Jung, M, Keum, KC, Yoon, J, Lee, S & Shin, SJ 2018, 'Prognoses and clinical outcomes of primary and recurrent uveal melanoma', Cancer Research and Treatment, vol. 50, no. 4, pp. 1238-1251. https://doi.org/10.4143/crt.2017.534

Prognoses and clinical outcomes of primary and recurrent uveal melanoma. / Kim, Jee Hung; Shin, Su Jin; Heo, Soo Jin; Choe, Eun Ah; Kim, Chang Gon; Jung, Minkyu; Keum, Ki Chang; Yoon, Jinsook; Lee, Sungchul; Shin, Sang Joon.

In: Cancer Research and Treatment, Vol. 50, No. 4, 01.10.2018, p. 1238-1251.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognoses and clinical outcomes of primary and recurrent uveal melanoma

AU - Kim, Jee Hung

AU - Shin, Su Jin

AU - Heo, Soo Jin

AU - Choe, Eun Ah

AU - Kim, Chang Gon

AU - Jung, Minkyu

AU - Keum, Ki Chang

AU - Yoon, Jinsook

AU - Lee, Sungchul

AU - Shin, Sang Joon

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood of recurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters. Materials and Methods Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression- free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy. Results Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)-negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival. Conclusion Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.

AB - Purpose Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood of recurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters. Materials and Methods Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression- free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy. Results Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)-negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival. Conclusion Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85054763299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054763299&partnerID=8YFLogxK

U2 - 10.4143/crt.2017.534

DO - 10.4143/crt.2017.534

M3 - Article

C2 - 29281872

AN - SCOPUS:85054763299

VL - 50

SP - 1238

EP - 1251

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -